MedTrace Logo

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

NCT04034745 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-12-30

No results posted yet for this study

Summary

This single arm study will evaluate whether Xermelo (telotristat ethyl) associated weight gain is affects lean body mass, dietary intake, and physical and cognitive functioning among neuroendocrine tumor (NET) patients with a history of carcinoid syndrome.

Conditions

Interventions

DRUG

telotristat ethyl

250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care

Sponsors & Collaborators

  • Lexicon Pharmaceuticals

    collaborator INDUSTRY

  • Andrew Hendifar, MD

    lead OTHER

Principal Investigators

  • Andrew Hendifar, MD, MPH · Cedars-Sinai Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2022-11-30
Completion
2023-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04034745 on ClinicalTrials.gov